1998
DOI: 10.1016/s0163-7258(98)00010-2
|View full text |Cite
|
Sign up to set email alerts
|

Chemopreventive Agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
160
0
5

Year Published

1999
1999
2021
2021

Publication Types

Select...
6
4

Relationship

1
9

Authors

Journals

citations
Cited by 289 publications
(170 citation statements)
references
References 242 publications
2
160
0
5
Order By: Relevance
“…Somewhat contrasting to these reports are the clinical use of chymotryptic protease inhibitors (e.g. AACT) as cancer suppressing agents [33].…”
Section: Validation Of the Lc-ms Datamentioning
confidence: 96%
“…Somewhat contrasting to these reports are the clinical use of chymotryptic protease inhibitors (e.g. AACT) as cancer suppressing agents [33].…”
Section: Validation Of the Lc-ms Datamentioning
confidence: 96%
“…Inh I and Inh II are effective proteinase inhibitors of chymotrypsin and trypsin (3,4) and have been reported to display anticarcinogenic properties by suppressing irradiation-induced transformation of mouse embryo fibroblasts (6). Although the mechanisms underlying these effects are poorly understood, the inhibition of chymotrypsin-like enzymes is believed to play an important role in the reported anticarcinogenic effect (30). We have previously demonstrated that blocking AP-1 activity inhibits tumor transformation, suggesting that AP-1 activity is necessary for tumor promoter-induced transformation (10).…”
Section: Resultsmentioning
confidence: 99%
“…Among its more prominent properties is that this protein remains intact after oral ingestion, inhibits a wide range of proteases, and has a chymotrypsin active site. The unique properties of this agent and the extensive activity of BowmanBirk inhibitor in in vitro assays and in animal models are summarized in several reviews (29,30); most relevant to this current discussion was the demonstration of activity in the hamster oral cheek pouch model in 1986 (31), and in 1992, the demonstration of mucosal proteases in exfoliated oral keratinocytes in humans (32). These data provided the basis for development of Bowman-Birk inhibitor as a drug, which was a formidable task.…”
Section: The Summer Years: Difluoromethylornithine and Bowman-birk Inmentioning
confidence: 99%